Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
University of Chicago
Neonc Technologies, Inc.
ImmunityBio, Inc.
Ohio State University Comprehensive Cancer Center
Incyte Corporation
Bristol-Myers Squibb
Incyte Corporation
Yale University
National Cancer Institute (NCI)